Prediction of adverse pregnancy outcome in patients with antiphospholipid antibodies

Sarita Chaudhary; Charusmita Agrawal; Deepak Kumar

doi:10.18203/2320-1770.ijrcog20161335

Authors

Sarita Chaudhary Department of Gynecology, Civil Hospital, Gurgaon, Uttar Pradesh, India
Charusmita Agrawal Department of Obstretics and Gynecology, SMS Hospital, Jaipur, Rajasthan, India
Deepak Kumar Consultant, Urosurgeon, Medanta Hospital, Gurgaon, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20161335

Keywords:

Pre-eclampsia, Prematurity, Recurrent fetal loss, Intrauterine growth retardation, Antiphospholipid antibody

Abstract

Background: Immunological cause play an important role in abnormal pregnancy outcome, in which antiphospholipid syndrome is one of the growing cause of concern. The objective of the study was to investigate serologic prediction of adverse pregnancy outcome in patients with antiphospholipid antibody (APL) and to test the hypothesis that a serologic variable can identify women at highest risk of adverse pregnancy outcome.

Methods: A cross sectional, observational study including total 250 pregnant women, divided in five groups including patients with recurrent abortion ,patients with IUGR, patients with pre eclampsia, patients with preterm labour having 50 patients each and control group of 50 pregnant females without any complications. Comparison of each group for the presence of anti phospholipid antibodies (both IgG and IgM) with control group was performed. Data collected were analyzed using appropriate statistical tests.

Results: Antiphospholipid antibodies in patients of obstetric and fetal complications were abnormally high. IgG antibody was found in pre-eclampsia (62%), prematurity (54%), recurrent fetal loss (44%) and intrauterine growth retardation (54%), IgM antibody was also found in pre-eclampsia (54%), prematurity (32%), recurrent fetal loss (30%) and intrauterine growth retardation (40%). Presence of IgG antiphospholipid antibody in comparison with controls is statistically significant in patient of preeclampsia and recurrent fetal loss.

Conclusions: Early autoimmune screening for antiphospholipid antibodies (IgM, IgG) of pregnant ladies was found to be effective tool in predilection of obstetric and fetal complications.

Metrics

Metrics Loading ...

References

Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J, American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edn). Chest. 2008;133(6Suppl):844S-86S.

Balasch J1, Creus M, Fábregues F, Reverter JC, Carmona F, Tàssies D et al. Antiphospholipid antibodies and human reproductive failure Hum Reprod. 1996;11(10):2310-5.

Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80:61420.

Parazzini F, Acaia B, Faden D. Antiphospholipid antibodies and recurrent miscarriage. Obstet Gynecol. 1991;77:854-8.

Kalra S, Tuli A, Goyal U, Choudhary R, Raheja S. Correlation of Anticardiolipin Antibody IgM With First Trimester Recurrent Abortions. Journal of the Anatomical Society of India. 2002;51(1):1-6.

Maier DB, Parke A. Subclinical autoimmunity in recurrent aborters. Fertil Steril. 1989 ;51(2):280-5.

Creagh MD, Malia RG, Cooper SM, Smith AR, Duncan SL. Screening for lupus anticoagulant and anticardiolipin antibodies in women with fetal loss. J Clin Pathol. 1991;44(1):45-7.

Lockwood CJ, Romero R, Feinberg RF. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in general obstetric population. American Journal of Obstetrics & Gynecology. 1989;16:369-73.

Cowchock S, Smith JB, Gocial B. (1986): Antibodies to phospholipids and nuclear antigens in patients with repeated abortions. American Journal of obstetrics & gynecology. 1986;155:1002-10.

Silver RK, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin A. (1993). Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol. 1993;169(6):1411-7.

Lockshin MD. Antiphospholipid antibody. J Am Med Assoc. 1997;277:1549-51.

Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80:61420.

Backos M, Rai R, Baxter N, Chilcott IT, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage. 1999;106(2):102-7.

Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996;14(2):131-6.

Clark EA, Silver RM, Branch DW. (2007). Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome? Curr Rheumatol Rep. 2007;9(3):219-25.